Other languages Humacyte, Inc.

Equities

HUMA

US44486Q1031

Real-time Estimate Cboe BZX Other stock markets 09:45:21 14/05/2024 pm IST			5-day change	1st Jan Change
6.6 ^USD	+20.44%		+42.08%	+130.63%

10/05	Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024
28/03	Transcript : Humacyte, Inc. - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Interest Rate, Monetary Policy Views Lift Wall Street Pre-Bell; Asia Mixed, Europe Up	22/03
Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Humacyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/03
Sector Update: Health Care Stocks Edge Higher Premarket Friday	01/03
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	01/03
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	10/02
Sector Update: Health Care Stocks Mixed in Afternoon Trading	10/02
Humacyte Shares Rise as Application for Potential Vascular Trauma Treatment Gets Priority Review from FDA	09/02
Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application	09/02
Humacyte Seeks FDA Approval of Bioengineered Tissue for Treatment of Vascular Injuries	12/12
Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel for the Treatment of Vascular Trauma	12/12
Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel?? (HAV??) in the Treatment of Vascular Trauma	17/11
Humacyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel?? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model	16/23/16
Humacyte Insider Sold Shares Worth $5,560,000, According to a Recent SEC Filing	16/23/16
Humacyte Insider Sold Shares Worth $5,560,000, According to a Recent SEC Filing	16/23/16
Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel?? (HAV??) in Treatment of Patients with Vascular Trauma	12/23/12
Humacyte to Unveil Phase 2/3 Results for Universally Implantable Bioengineered Human Tissue Study; Shares Jump Premarket	12/23/12
Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic	11/23/11
Insider Sell: Humacyte	22/23/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Humacyte, Inc.

Equities

HUMA

US44486Q1031

Other languages

Filters